Merck Long Term Debt Total vs Short Term Debt Analysis
MRK Stock | USD 131.20 0.48 0.37% |
Merck financial indicator trend analysis is infinitely more than just investigating Merck Company recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Merck Company is a good investment. Please check the relationship between Merck Long Term Debt Total and its Short Term Debt accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Long Term Debt Total vs Short Term Debt
Long Term Debt Total vs Short Term Debt Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Merck Company Long Term Debt Total account and Short Term Debt. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Merck's Long Term Debt Total and Short Term Debt is -0.13. Overlapping area represents the amount of variation of Long Term Debt Total that can explain the historical movement of Short Term Debt in the same time period over historical financial statements of Merck Company, assuming nothing else is changed. The correlation between historical values of Merck's Long Term Debt Total and Short Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Long Term Debt Total of Merck Company are associated (or correlated) with its Short Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Term Debt has no effect on the direction of Long Term Debt Total i.e., Merck's Long Term Debt Total and Short Term Debt go up and down completely randomly.
Correlation Coefficient | -0.13 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Long Term Debt Total
Short Term Debt
Most indicators from Merck's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Merck Company current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. At this time, Merck's Selling General Administrative is quite stable compared to the past year. Sales General And Administrative To Revenue is expected to rise to 0.18 this year, although the value of Tax Provision will most likely fall to about 2.2 B.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 35.1B | 41.9B | 43.9B | 46.1B | Total Revenue | 48.7B | 59.3B | 59.9B | 32.5B |
Merck fundamental ratios Correlations
Click cells to compare fundamentals
Merck Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Merck fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 84.4B | 91.6B | 105.7B | 109.2B | 106.7B | 60.3B | |
Short Long Term Debt Total | 26.3B | 31.8B | 33.1B | 30.7B | 36.3B | 38.1B | |
Other Current Liab | 14.9B | 16.3B | 16.9B | 18.0B | 15.5B | 16.3B | |
Total Current Liabilities | 22.2B | 27.3B | 23.9B | 24.2B | 25.7B | 13.3B | |
Total Stockholder Equity | 25.9B | 25.3B | 38.2B | 46.0B | 37.6B | 25.5B | |
Property Plant And Equipment Net | 15.1B | 18.0B | 19.3B | 21.4B | 24.5B | 25.7B | |
Net Debt | 16.7B | 23.7B | 25.0B | 18.0B | 29.4B | 30.8B | |
Retained Earnings | 46.6B | 47.4B | 53.7B | 61.1B | 53.9B | 32.6B | |
Cash | 9.7B | 8.1B | 8.1B | 12.7B | 6.9B | 5.6B | |
Non Current Assets Total | 56.9B | 63.8B | 75.4B | 73.4B | 74.5B | 41.1B | |
Non Currrent Assets Other | 5.3B | 9.2B | 8.1B | 7.7B | 9.2B | 6.1B | |
Cash And Short Term Investments | 10.5B | 8.1B | 8.1B | 13.2B | 7.2B | 7.3B | |
Net Receivables | 6.8B | 7.9B | 9.2B | 9.5B | 11.1B | 11.6B | |
Common Stock Shares Outstanding | 2.6B | 2.5B | 2.5B | 2.5B | 2.5B | 2.7B | |
Liabilities And Stockholders Equity | 84.4B | 91.6B | 105.7B | 109.2B | 106.7B | 60.3B | |
Non Current Liabilities Total | 36.2B | 38.9B | 43.6B | 38.9B | 43.3B | 45.5B | |
Inventory | 6.0B | 6.3B | 6.0B | 5.9B | 6.4B | 3.7B | |
Other Current Assets | 4.3B | 5.5B | 7.0B | 7.2B | 7.6B | 8.0B | |
Other Stockholder Equity | (16.3B) | (17.2B) | (12.9B) | (12.1B) | (12.9B) | (12.3B) | |
Total Liab | 58.4B | 66.2B | 67.4B | 63.1B | 69.0B | 72.5B | |
Total Current Assets | 27.5B | 27.8B | 30.3B | 35.7B | 32.2B | 19.2B | |
Short Term Debt | 3.6B | 6.4B | 2.4B | 1.9B | 1.7B | 2.3B | |
Intangible Assets | 14.2B | 14.6B | 22.9B | 20.3B | 18.0B | 14.3B | |
Accounts Payable | 3.7B | 4.6B | 4.6B | 4.3B | 3.9B | 2.8B | |
Property Plant And Equipment Gross | 15.1B | 18.0B | 37.5B | 39.4B | 41.3B | 43.4B | |
Accumulated Other Comprehensive Income | (6.2B) | (6.6B) | (4.4B) | (4.8B) | (5.2B) | (4.9B) | |
Short Term Investments | 774M | 1M | 0.0 | 498M | 252M | 239.4M | |
Other Liab | 12.7B | 12.1B | 11.7B | 9.1B | 10.5B | 10.2B | |
Other Assets | 5.3B | 7.8B | 9.4B | 7.4B | 8.5B | 5.5B | |
Long Term Debt | 22.7B | 25.4B | 30.7B | 28.7B | 33.7B | 17.2B | |
Good Will | 19.4B | 20.2B | 21.3B | 21.2B | 21.2B | 12.3B | |
Treasury Stock | (56.0B) | (56.8B) | (57.1B) | (56.5B) | (57.5B) | (54.6B) | |
Property Plant Equipment | 15.1B | 18.0B | 19.3B | 21.4B | 24.6B | 16.2B | |
Net Tangible Assets | (7.7B) | (9.5B) | 3.5B | 4.5B | 4.1B | 4.5B | |
Noncontrolling Interest In Consolidated Entity | 94M | 87M | 73M | 67M | 54M | 51.3M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Complementary Tools for Merck Stock analysis
When running Merck's price analysis, check to measure Merck's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merck is operating at the current time. Most of Merck's value examination focuses on studying past and present price action to predict the probability of Merck's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merck's price. Additionally, you may evaluate how the addition of Merck to your portfolios can decrease your overall portfolio volatility.
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |
Is Merck's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Merck. If investors know Merck will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Merck listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.453 | Dividend Share 2.92 | Earnings Share 0.14 | Revenue Per Share 23.695 | Quarterly Revenue Growth 0.058 |
The market value of Merck Company is measured differently than its book value, which is the value of Merck that is recorded on the company's balance sheet. Investors also form their own opinion of Merck's value that differs from its market value or its book value, called intrinsic value, which is Merck's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Merck's market value can be influenced by many factors that don't directly affect Merck's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Merck's value and its price as these two are different measures arrived at by different means. Investors typically determine if Merck is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merck's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.